Podcasts about bioscience

What if the future of skincare wasn't about trends — but about real science and long-term skin health? On today's episode, we welcome Dr. Dhaval Bhanusali, board-certified dermatologist and co-founder of Elm Biosciences — a company combining in-office treatments with smarter at-home routines. If you're interested in understanding the science behind skincare, making better decisions for your skin, or staying ahead of where the industry is going — this one's for you. Tune in now on The Kara Goldin Show.   Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks.   To learn more about Dr. Dhaval Bhanusali and Elm Biosciences:https://elmbiosciences.com/https://www.instagram.com/dhbhanusali/https://www.linkedin.com/in/dhaval-bhanusali/https://bhanusalimd.com/   Sponsored By: Fatty15 - Get an additional 15% off a 90-day subscription Starter Kit by going to Fatty15.com/KARA and using code KARA at checkout. Acorns - Head to Acorns.com/KARA or download the Acorns app to get started. LinkedIn Jobs - Head to LinkedIn.com/KaraGoldin to post your job for free. Upwork - Visit Upwork.com right now and post your job for free. Rippling - Head to Rippling.AI/KaraGoldin and get the only AI to give you full visibility across your business and take complex actions across your entire organization.   Check out our website to view this episode's show notes: https://karagoldin.com/podcast/852

We add another string to our bow by learning about the fiddler crab. We discuss the arc of history bending towards crab, the MogBot 2000, bad dating advice, non-orientable wormholes, and so much more.  Works Cited: “The Design of a Beautiful Weapon” - John Christy, Smithsonian Museum of Natural History “On the Other Hand: The Myth of Fiddler Crab Claw Reversal” - Judith S. Weis, BioScience, April 2019 “Sexual selection for structure building by courting male fiddler crabs: an experimental study of behavioral mechanisms” - John H. Christy et al., Behavioral Ecology, May 2002 “Synchronous waving in fiddler crabs: a review” - Patricia Ruth Yvonne Backwell, Current Zoology, July 2018 “Robotic crabs reveal that female fiddler crabs are sensitive to changes in male display rate” - Sophie L. Mowles et al., Biology Letters, January 2018 “Not what it looks like: mate-searching behaviour, mate preferences and clutch production in wandering and territory-holding female fiddler crabs” - M. Peso et al., R. Soc Open Sci.. August 2016 “Dishonest signalling of fighting ability and multiple performance traits in the fiddler crab Uca mjoebergi” - Simon P. Lailvaux et al., Functional Ecology, March 2009 “The effects of neighbor familiarity and size on cooperative defense of fiddler crab territories” - Isobel Booksmythe et al., Behavioral ecology, November 2011 “Beyond Abiotic Decay: Fiddler Crabs Accelerate Plastic Fragmentation in Pollution Hotspots” - Jose M. Riascos et al., Global Change Biology, December 2025 Links: For more information about us & our podcast, head over to our website! Follow Just the Zoo of Us on BlueSky, Facebook, Instagram & Discord! Follow Ellen on Instagram or BlueSky!   Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joinjustthezoo

We add another string to our bow by learning about the fiddler crab. We discuss the arc of history bending towards crab, the MogBot 2000, bad dating advice, non-orientable wormholes, and so much more.  Works Cited: “The Design of a Beautiful Weapon” - John Christy, Smithsonian Museum of Natural History “On the Other Hand: The Myth of Fiddler Crab Claw Reversal” - Judith S. Weis, BioScience, April 2019 “Sexual selection for structure building by courting male fiddler crabs: an experimental study of behavioral mechanisms” - John H. Christy et al., Behavioral Ecology, May 2002 “Synchronous waving in fiddler crabs: a review” - Patricia Ruth Yvonne Backwell, Current Zoology, July 2018 “Robotic crabs reveal that female fiddler crabs are sensitive to changes in male display rate” - Sophie L. Mowles et al., Biology Letters, January 2018 “Not what it looks like: mate-searching behaviour, mate preferences and clutch production in wandering and territory-holding female fiddler crabs” - M. Peso et al., R. Soc Open Sci.. August 2016 “Dishonest signalling of fighting ability and multiple performance traits in the fiddler crab Uca mjoebergi” - Simon P. Lailvaux et al., Functional Ecology, March 2009 “The effects of neighbor familiarity and size on cooperative defense of fiddler crab territories” - Isobel Booksmythe et al., Behavioral ecology, November 2011 “Beyond Abiotic Decay: Fiddler Crabs Accelerate Plastic Fragmentation in Pollution Hotspots” - Jose M. Riascos et al., Global Change Biology, December 2025 Links: For more information about us & our podcast, head over to our website! Follow Just the Zoo of Us on BlueSky, Facebook, Instagram & Discord! Follow Ellen on Instagram or BlueSky!   Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joinjustthezoo

10x Genomics, Inc. v. Parse Biosciences, Inc.

Tune in as Jennifer Mondillo, a gerontology nurse practitioner, and Rob Leffler, a board-certified geriatric pharmacist, explain the inappropriate use of anticholinergic medications to treat older adults with tardive dyskinesia (TD), a drug-induced movement disorder. These experts emphasize the importance of reducing or eliminating the anticholinergic burden in patients with TD and discuss practical approaches to evaluating anticholinergic use in LTC residents with drug-induced movement disorders, de-prescribing, and treating TD appropriately with VMAT2 inhibitors. This podcast was sponsored and co-developed by Neurocrine Biosciences, Inc.” This podcast is an educational program sponsored and co-developed by Neurocrine Biosciences.Neurocrine Biosciences is a pioneering company with over 30 years of experience dedicated to discovering and developing life-changing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Learn more: https://www.neurocrine.com/Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

For decades, men had Viagra. Women were told to relax and have a glass of wine. That imbalance in pharmaceutical innovation is finally changing, but it hasn't been easy.In this episode, I talk with Sabrina Johnson, the founder and CEO of Dare Bioscience the only publicly traded pharmaceutical company focused entirely on women's healthcare. We discuss why the pharmaceutical industry has historically avoided investing in women's sexual health, the stigma and sexism that surrounds female arousal and pleasure, and what it actually takes to develop and bring products to market.Sabrina walks us through the development of Dare to Play, a topical cream for sexual arousal that's coming soon, the science behind how it works, and the extensive clinical trials required to prove safety and efficacy. We also discuss other products in development a probiotic for vaginal health and a once-a-month vaginal ring for menopause with estradiol and progesterone. This is about changing what's possible for women's health.From regulatory hurdles to cultural stigma, the barriers to innovating in women's sexual health are real. In this conversation, we explore how companies can create real world solutions that actually work for women's lives, the importance of rigorous clinical testing, and why investing in women's health matters. We dive into the science, the business side, and how you can support this work.Highlights:Only 1% of private investment in pharmaceutical development goes to companies innovating solely for women which is why there's so little funding and so many gaps.The stigma is real: one NPR station refused to air an interview because Sabrina said the word "vagina" too many times.Dare to Play increases blood flow to genital tissue for sensation and lubrication the same mechanism as Viagra, but in cream form. The major innovation was developing specialized delivery technology to get sildenafil through skin and manufacturing at pharmaceutical grade standards rather than compounding standards.Dare worked with the SEC and NASDAQ to create a direct public offering so anyone can invest with just $250, not just institutional investors.I hope this episode inspires you to think differently about women's health innovation and what's possible when we demand better. If you believe in the work DARE is doing, you can support it. You don't have to donate you can become an investor with as little as $250. All the information on how to do that will be below.Get in touch with Sabrina:WebsiteBecome an InvestorInstagramLinkedInTikTokGet in Touch with Me:WebsiteInstagramYoutubeSubstack

Most of us instinctively understand that we feel better when we spend time in nature. But our relationship to the natural world is perhaps even more powerful than we appreciate. On today's episode, host Rachel is joined by Emily Long—licensed clinical social worker, certified nature-informed therapist, and yoga teacher. Emily shares research on the therapeutic benefits of building a more mindful relationship with nature, whether that means spending time outdoors, inviting natural elements indoors, even simply viewing nature through a window. Emily also reminds us how nature is deeply embedded in the yoga tradition.  From stress reduction and improved cognitive function to increased resilience and emotional regulation, this conversation highlights the many ways reconnecting with nature can support our well-being, and how our practice could be the perfect time and place to do so. "What we care for cares for us." — Emily Long. — What You'll Learn: • How yoga already reflects our connection to nature [3:08] • Stereotypes can discourage people from developing a relationship with nature [9:19] • Research: nature and our health [12:56] • "Softly fascinating stimuli" and the nervous system [16:12] • Reaping the benefits whether we enjoy nature or not [20:40] • Nature encourages social and community connection [23:44] • Practical ways to invite nature into indoor spaces [26:35] • Taking opportunities to go outside [29:02] • Natural imagery, honoring seasonal rhythms [30:59] • Ahimsa, reciprocity, and caring for the environment [37:33] — Links Mentioned: Watch this episode on YouTube Relevant research: Soga, M., & Gaston, K. J. (2025). Health benefits of viewing nature through windows: A meta-analysis. Bioscience, 75(8), 628–636. https://doi.org/10.1093/biosci/biaf089 Stevenson, M. P., Schilhab, T., & Bentsen, P. (2018). Attention Restoration Theory II: a systematic review to clarify attention processes affected by exposure to natural environments. Journal of toxicology and environmental health. Part B, Critical reviews, 21(4), 227–268. https://doi.org/10.1080/10937404.2018.1505571 Bettmann, J. E., Speelman, E., Blumenthal, E., Couch, S., & McArthur, T. (2024). How Does Nature Exposure Affect Adults With Symptoms of Mental Illness? A Meta-Analysis. International journal of mental health nursing, 33(6), 1889–1907. https://doi.org/10.1111/inm.13400 Ulrich R. S. (1984). View through a window may influence recovery from surgery. Science (New York, N.Y.), 224(4647), 420–421. https://doi.org/10.1126/science.6143402  Connect with Emily Long: Instagram | Yoga With Emily | Emily Long LCSW — Learn More: Find the full show notes at YogaMedicine.com/podcast-168. Learn more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts or wherever you listen to podcasts. 

GreenLight Biosciences' Jonathan Adamson says they've shown that RNA can be a viable solution to control the pests that potato growers deal with regularly.

May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

We love to hear from our listeners. Send us a message.This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field. Dr. Gorsuch discusses how Precision Biosciences approaches in vivo therapeutic development through its Arcus platform, with programs targeting chronic hepatitis B and Duchenne muscular dystrophy. They cover the broader challenges facing in vivo gene editing, including delivery limitations outside the liver, balancing specificity and efficiency, mitigating off-target risks, and translating promising preclinical in vivo data into clinical success.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Headlines warned us about microplastics in our brains. A chemist says the study may have been measuring brain fat instead. In 2025, a study claiming microplastics accumulate in human brain tissue dominated our feeds. We covered it. Then Dr. Michelle Wong, a chemical scientist and science communicator, flagged a problem with the methodology. So we went to the primary literature, read the critique, and brought in one of the first scientists to publicly challenge the findings: Dr. Oliver Jones, Professor of Analytical Chemistry at RMIT University in Melbourne. In this episode, we unpack what went wrong with the measurement method, what it means for the broader microplastics conversation, and why being willing to say "I was wrong" is so vital for good science. In this episode: How pyrolysis GC-MS works and why it can confuse plastic breakdown products with brain fat Why potassium hydroxide digestion creates soap, which also mimics plastic signatures The contamination problem: body bags, centrifuge tubes, plastic storage containers, and lab air Why 7 grams of microplastic per brain is more than what researchers find in raw sewage The Marfella study in The New England Journal of Medicine: microplastics in arterial plaques and why it also lacked blank controls How microplastics could enter the body: skin absorption, ingestion, and inhalation Why PM2.5 monitoring already captures the most relevant airborne microplastic exposure What the WHO, FDA, and European Food Safety Authority have concluded about microplastic harm What better microplastics research would actually look like Why the real lesson is about how we evaluate headlines, not just microplastics Dr. Oliver Jones is Professor of Analytical Chemistry and Associate Dean of Biosciences and Food Technology at RMIT University in Melbourne. A Fellow of the Royal Society of Chemistry (FRSC) and the Royal Australian Chemical Institute (FRACI), he holds degrees from Imperial College London and Cambridge. He is one of only 118 scientists worldwide named to the IUPAC Periodic Table of Outstanding Younger Chemists. His research focuses on developing methods to measure environmental contaminants, including microplastics, and he was among the first scientists to publicly challenge the methodology of the viral "microplastics in the brain" study. Follow Dr. Jones: @dr_oli_jones RMIT faculty page: rmit.edu.au/oliver-jones Dr. Michelle Wong (Lab Muffin Beauty Science) first flagged the methodological concerns to us. Hosted by Drs. Ayesha & Dean Sherzai Subscribe to The Synapse (free weekly newsletter): https://thebraindocs.com/newsletter  Follow @TheBrainDocs on Instagram

For this episode, we're joined by Jesse Nippert, Professor in Biology at Kansas State University, and Chris Helzer, Director of Science and Stewardship for the Nature Conservancy in Nebraska. They were on the show to discuss their recent BioScience article "Rethinking grassland management in the Great Plains during the era of woody plant encroachment."

Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,” Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.See omnystudio.com/listener for privacy information.

Dr. Javier Szwarcberg, CEO of Spruce Biosciences,  is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children.  The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain.  The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier explains, "It's a devastating, profoundly affecting disease whereby children are typically born normally and born asymptomatic. And over time, they develop an accumulation of a toxic substrate throughout the body, but primarily the brain. And because of that, it eventually results in a fairly young age, usually between two and a half and I would say three and a half, in symptoms starting. That toxic substance builds in throughout the brain and starts affecting initially learning behavior. Sleep patterns are very much affected, whereby children don't sleep at night and sleep during the day, and they're very hyperactive. And sometimes the diagnosis is confused, and there's no clarity as to what is going on with the child, early in the onset of the disease."   "Yes, it's a genetic disease that's inherited. There's a missing enzyme responsible for the metabolism of this toxic substrate, which I talked about, called heparan sulfate. So when heparan sulfate builds up in the brain, it causes inflammation and neurotoxicity, ultimately resulting in neurodegeneration. Think about it as a disease that is very similar to what you end up seeing with Alzheimer's, whereby the toxic substrate in Alzheimer's is between neurons and outside of the actual cell. In this case, in this disease, the toxic substance, which is different than the one that accumulates in Alzheimer's but builds within the neural cells. Yes, so that's very well-known and very well-characterized." #SpruceBio #SanfilippoSyndrome #MPSIIIB #CureSanfilippo #RareDiseases #EnzymeReplacementTherapy #LysosomalStorageDisorders #BiopharmaceuticalInnovation #ClinicalTrials #RareDiseaseResearch #HealthcareInnovation #PrecisionMedicine sprucebio.com Download the transcript here

Dr. Javier Szwarcberg, CEO of Spruce Biosciences,  is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children.  The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain.  The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier explains, "It's a devastating, profoundly affecting disease whereby children are typically born normally and born asymptomatic. And over time, they develop an accumulation of a toxic substrate throughout the body, but primarily the brain. And because of that, it eventually results in a fairly young age, usually between two and a half and I would say three and a half, in symptoms starting. That toxic substance builds in throughout the brain and starts affecting initially learning behavior. Sleep patterns are very much affected, whereby children don't sleep at night and sleep during the day, and they're very hyperactive. And sometimes the diagnosis is confused, and there's no clarity as to what is going on with the child, early in the onset of the disease."   "Yes, it's a genetic disease that's inherited. There's a missing enzyme responsible for the metabolism of this toxic substrate, which I talked about, called heparan sulfate. So when heparan sulfate builds up in the brain, it causes inflammation and neurotoxicity, ultimately resulting in neurodegeneration. Think about it as a disease that is very similar to what you end up seeing with Alzheimer's, whereby the toxic substrate in Alzheimer's is between neurons and outside of the actual cell. In this case, in this disease, the toxic substance, which is different than the one that accumulates in Alzheimer's but builds within the neural cells. Yes, so that's very well-known and very well-characterized." #SpruceBio #SanfilippoSyndrome #MPSIIIB #CureSanfilippo #RareDiseases #EnzymeReplacementTherapy #LysosomalStorageDisorders #BiopharmaceuticalInnovation #ClinicalTrials #RareDiseaseResearch #HealthcareInnovation #PrecisionMedicine sprucebio.com Listen to the podcast here

On this episode of The Hennessy Report, Dave Hennessy is joined by Robert Buckley, Chief People Architect at Enveda Biosciences, alongside colleague Jill Thompson, for a conversation on modern HR leadership, people strategy, and building high-performing cultures. Key topics include: • Principle-based leadership vs. policy-driven HR • Coaching-style management and developing stronger people leaders • Using data and analytics to improve HR decision-making • The impact of microlearning and continuous leadership development • Building a people-first culture in fast-growing organizations • Executive career decision-making with Howard Seidel in Coach's Corner A practical, forward-thinking discussion for HR leaders navigating leadership development, employee experience, and organizational growth.

In this episode, UBC's Associate Vice-President, Campus and Community Planning, Michael White, joins Carol and Jeevan to break down the SkyTrain to UBC project—the planned Millennium Line extension to UBC. Michael explains why the Broadway Subway Project is insufficient, how the Arbutus station will already be over capacity on day one, and why completing the line to UBC is the only real solution. He outlines the project's sweeping benefits: thousands of new housing units, major greenhouse gas reductions, and billions in economic opportunity. He also shares what it takes to align governments, nations, and communities around a shared vision—and why your voice matters.Links for this episodeTranscriptSkyTrain to UBC websiteLearn more about the UBCx planAbout Michael WhiteMario Canseco: Three in four Metro Vancouverites want SkyTrain extended to UBC, poll findsOpinion: UBC SkyTrain must be Metro Vancouver's next public transit priorityContact CarolContact JeevanFrom Here ForwardPodium Podcast Company (00:00) - Introduction (01:39) - Meet Michael White (02:02) - What is UBCx, why is it needed, and it's potential benefits (06:50) - Current project status & stakeholder groups (11:12) - The economic case for UBCx (12:33) - Addressing concerns (14:28) - The importance of effective up-front engagement (16:39) - Making planning personal (18:14) - What urban planners really do (19:40) - Work-life sustainability (20:44) - A listener call-to-action (22:05) - Conclusion

This week on The Hamilton Review Podcast, we're pleased to welcome Dr. Stephanie Culler. Stephanie Culler, Ph.D., is the co-founder and CEO of Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines. In this episode, Dr. Culler shares about all about the company, including how a first-of-its-kind combination of probiotics and prebiotics replenishes key Bifidobacterium linked to healthier digestion, improved sleep and immune development for your baby. Parents, don't miss this informative conversation. Stephanie Culler, Ph.D., is the co-founder and CEO of Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines. Her microbiome interests span applications ranging from infant health to oncology and food as medicine. She has shared her work at TEDx San Diego, has been published in Science Magazine, and is a scientific pioneer in the field of synthetic biology. Stephanie holds a Ph.D. from the California Institute of Technology and has authored over twenty publications and patents on synthetic biology and microbial-based technologies.   How to contact Stephanie Culler:   Persephone Biosciences, Inc.   Persephone on Instagram   Persephone on LinkedIn   Persephone on TikTok     How to contact Dr. Bob: Dr. Bob on YouTube: https://www.youtube.com/channel/UChztMVtPCLJkiXvv7H5tpDQ Dr. Bob on Instagram: https://www.instagram.com/drroberthamilton/ Dr. Bob on Facebook: https://www.facebook.com/bob.hamilton.1656 Dr. Bob's Seven Secrets Of The Newborn website: https://7secretsofthenewborn.com/ Dr. Bob's website: https://roberthamiltonmd.com/ Pacific Ocean Pediatrics: http://www.pacificoceanpediatrics.com/    

Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production. Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich's ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day." "So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich's ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs." "In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well."   #SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences solidbio.com Download the transcript here

Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production. Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich's ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day." "So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich's ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs." "In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well."   #SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences solidbio.com Listen to the podcast here

Join us for a deep dive with Ritish Patnaik, CEO of Curve Biosciences, on building “whole-body intelligence” for chronic disease. Ritish shares how Curve's whole-body atlas, built from hundreds of thousands of curated tissue samples, powers blood tests that map DNA methylation signals back to their organ of origin. We explore how this approach overcomes the signal-to-noise challenge in blood-based diagnostics, enables longitudinal monitoring of diseases like liver cirrhosis and MASH, and rethinks how patients are guided through treatment. Ritish also reflects on the role of AI, data curation, and multidisciplinary thinking in shaping the future of healthcare. Hosted by Ella Yee.

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss a landmark collaboration with Acuitas Therapeutics, the lipid nanoparticle specialist whose technology underpinned some of the most successful COVID-19 vaccines ever made. Leire described it as one of the most significant partnerships Genflow has signed, giving the company access to the gold standard in mRNA delivery technology - fully funded by Acuitas, with no cash cost and no dilution to shareholders. The collaboration will combine Genflow's proprietary SIRT6 payload with Acuitas' clinically validated LNP platform, generating preclinical data to support future clinical development and partnering discussions. Leire positioned the deal as a potential inflexion point, transitioning Genflow from a science story into a tangible clinical and commercial opportunity. For more videos like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss an update. #GenflowBiosciences #EricLeire #BiotechNews #SIRT6 #mRNA #LNP #Acuitas #BiotechInvesting #HealthcareInnovation #DrugDevelopment #ClinicalTrials #LifeSciences #InvestingNews #ProactiveInvestors

What if the future of marketing is not just knowing what people will do, but understanding why they feel the way they do? In this episode, Joy Allen-Altimare unpacks predictive emotional modelling, and why the next leap in data driven marketing will come from combining behaviour, context and human emotion.

Can we control a virtual body as naturally as our own—using only brain activity? This question, inspired by the iconic series Sword Art Online, was set by Taiga Seri, a PhD researcher at Keio University. Answering this question led Taiga to the nomination for the International BCI Award, bringing all of us one step closer to a future once imagined in science fiction.

This CEO Is Creating A Vaccine To Cure Breast Cancer - Meet Dr. Amit Kumar, Chairman/CEO of Anixa Biosciences $ANIXGuestDr. Amit Kumar, Chairman and CEO of Anixa BiosciencesAnixa Biosciences, www.Anixa.com, NASDAQ:ANIXCompany InfoAnixa BiosciencesNASDAQ:ANIXhttps://www.Anixa.com/Amit's Bio:AMIT KUMAR, PH.D.Chairman & Chief Executive OfficerDr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market.He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences and he sits on the Board of other public and private companies.He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.Company Bio:Anixa is a biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutics portfolio consists of a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.Anixa's vaccine portfolio consists of technology focused on the immunization against specific “retired” proteins associated with breast cancer, specifically triple negative breast cancer (TNBC), and ovarian cancer. Further, Anixa is developing additional “retired tissue specific protein” vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. Retired proteins are proteins that are expressed at certain times in life and then are no longer expressed in healthy people.Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

For today's episode, we're joined by Luiza F. A. de Paula, Vanessa Handley, Raphael Ocelli, and Peggy Fielder, who are four of the authors of the recent BioScience article "Beyond Scents: Calling on the Fragrance Industry to Champion Plant Diversity." In it, they describe The Red List Project, which is a conservation-first initiative that pairs partners from the fragrance industry with local environmental groups and communities to achieve biodiversity objectives and safeguard biocultural heritage, while creating viable fragrance products.  Learn more about one of the initiatives discussed in the podcast, the Magnolia masphi fragrance, in this podcast episode from Beyond the Journey.

Governor Braun commits $1 billion to bioscience sector growth, aiming to create 100,000 jobs over 10 years. Indiana ranked worst of all states for foreclosure filing rates, with Indianapolis and Evansville among the top 5 of cities with the highest rates. The FSSA could end Medicaid drug reimbursement for qualified health centers state-wide. Host Jill Sheridan is joined by political strategist Elise Shrock, Republican Chris Mitchem, Samantha Horton of WFYI, and Niki Kelly of the Indiana Capital Chronicle to debate and discuss this week's top stories.

Governor Braun commits $1 billion to bioscience sector growth, aiming to create 100,000 jobs over 10 years. Indiana ranked worst of all states for foreclosure filing rates. The FSSA could end Medicaid drug reimbursement for qualified health centers.

Interview with Dr. Mark Williams, President & CSO, and  J. Roderick Matheson, Director & CEO of Marvel Bioscience Corp.Recording date: 16th March 2026Marvel Biosciences is advancing MB-204, a first-in-class treatment for social withdrawal conditions across autism spectrum disorder, depression, and Alzheimer's disease. The clinical-stage biotechnology company targets an underserved therapeutic area affecting millions globally, with autism prevalence reaching one in 36 children in the United States and depression impacting one in eight adults currently on antidepressants. The addressable market spans hundreds of billions of dollars in healthcare costs and lost productivity.The compound is based on a modified version of an approved Parkinson's medication, providing an established safety foundation for clinical development. Preclinical data demonstrates rapid symptom reversal within one hour of oral dosing in animal models. In head-to-head comparisons, MB-204 outperformed trofinetide, the only FDA-approved Rett syndrome treatment, across all measured behavioral endpoints. Critically, animals treated with MB-204 maintained improvements for two to three weeks after treatment cessation, suggesting semi-permanent neurological changes, while trofinetide benefits disappeared immediately upon stopping.Marvel's clinical strategy prioritizes orphan disease indications, specifically Rett syndrome and Fragile X syndrome, where Phase 3 success rates exceed 50% due to genetically homogeneous patient populations and validated regulatory pathways. The company has completed manufacturing of clinical-grade material and toxicology studies, positioning MB-204 for immediate Phase 1 entry in Australia within six to twelve months. The Australian regulatory environment offers efficient processes and a 43% research tax credit that significantly reduces development costs.Marvel holds composition of matter patents in China and Japan, with additional jurisdictions pending. The company has engaged in preliminary partnership discussions, aligning with neuroscience sector dynamics where approximately 70% of companies complete licensing or acquisition deals before Phase 2. Historical precedents show neuroscience acquisitions typically occur at valuations exceeding $80 million at this stage. Trading at $9 million CAD market capitalization, Marvel represents a significant discount to comparable Phase 1 neuroscience firms, with several peers valued between $100-400 million.Sign up for Crux Investor: https://cruxinvestor.com

Send a textIn this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Stephanie Culler, co-founder and CEO of Persephone Biosciences, to explore one of the most rapidly evolving frontiers in modern health science: the human microbiome. From early immune development to cancer therapy, the conversation reveals how the trillions of microbes living in our bodies may shape health in ways scientists are only beginning to understand.Dr. Culler's path into microbiome research began with a personal mission to understand disease after losing both of her grandmothers to cancer. Following her PhD at the California Institute of Technology, where she studied gene therapy approaches to cancer, she moved into industrial biotechnology and microbial engineering. That work eventually led her to co-found Persephone Biosciences, a company focused on translating microbiome science into real-world therapeutics and consumer health solutions.A major focus of the discussion centers on the infant microbiome and its role in shaping immune development. Dr. Culler explains how microbes transferred during birth and nourished through breast milk help “train” the immune system in the earliest stages of life. Yet modern research suggests that key beneficial bacteria—particularly Bifidobacterium infantis—have dramatically declined in Western infants. In large-scale studies conducted by Persephone, only a small percentage of U.S. infants carry adequate levels of this once-dominant microbe.The conversation also explores how microbiome balance may influence responses to cutting-edge cancer treatments like immunotherapy. Emerging research suggests that gut bacteria can significantly affect how patients respond to checkpoint inhibitors, opening the door to microbiome-based interventions that could enhance treatment outcomes.Listen to the full episode to hear Dr. Stephanie Culler explain how microbiome science is transforming our understanding of immunity, disease prevention, and the future of medicine.Learn more about Persephone BiosciencesDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

En este episodio hablamos con la Dra. Kelly Weinersmith, bióloga, parasitóloga y autora de ciencia popular. Kelly es investigadora asociada y profesora adjunta en el Departamento de BioSciences de Rice University, y su trabajo se centra en parásitos que manipulan el comportamiento de sus huéspedes, uno de los fenómenos más fascinantes de la biología. Además de su investigación científica, Kelly es conocida por acercar la ciencia al público a través de libros, charlas y podcasts. Es coautora de los bestsellers “Soonish” y “A City on Mars”, donde explora tecnologías emergentes y los retos reales de colonizar otros planetas. En la conversación hablamos sobre su investigación en parasitología, cómo los parásitos pueden controlar a otros organismos, el papel de la ciencia en el podcasting y la divulgación, y también nos adentramos en una de las grandes preguntas del futuro: si realmente podríamos vivir en Marte y qué problemas biológicos tendríamos que resolver para hacerlo posible.http://www.weinersmith.com/https://www.iheart.com/podcast/105-daniel-and-kellys-extraord-29862087/https://www.instagram.com/curiosidacientificapodcasthttps://jaboneradongato.com/Codigo; Curiosidad

Send a textIn this episode of the Small-Cap Spotlight, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa' clinical pipeline and strategic direction. He outlines the company's plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes the striking efficacy signals emerging from the Phase 1 study of Lira‑Cel, Anixa' CAR‑T therapy for ovarian cancer, observed in a terminally ill patient population. Dr. Kumar also details key protocol enhancements in the ongoing Phase 1 trial, to help steer the program toward potentially groundbreaking curative outcomes. Finally, supported by Anixa's capital‑efficient business model, Dr. Kumar notes that the expansion of clinical data in 2026 could drive meaningful opportunities for pharma partnerships and further validate the company's broader immunotherapy strategy.

Powering the Future with India's Ancient WisdomProf Ganti Suryanarayana Murthy is the National Coordinator of the Indian Knowledge Systems (IKS) Division, Ministry of Education, Government of India, at AICTE, New Delhi. He also serves as Professor in the Department of Biosciences and Biomedical Engineering at IIT Indore.He was among the distinguished guest speakers at the 2nd Global Vedic Conference held at Prasanthi Nilayam in January 2026, where he offered valuable insights from the integrated perspective of Indian Knowledge Systems, contemporary science, and education.Subsequently, during his interaction at the Sri Sathya Sai Media Centre, he eloquently expounded on the relevance, revival, and renaissance of ancient India's sacred knowledge traditions, highlighting their enduring significance in the modern world.

Brian Stolz has cracked the code — literally and figuratively — on what it takes to build thriving teams in biotech. Episode 110 of The Hennessy Report by Keystone Partners features Brian Stolz, Chief People Officer at Element Biosciences, joined by Keystone Partners West Coast Market Leader Charlene Hutchins. Brian shares how growing up in Tokyo shaped his global perspective, his philosophy on building high-performing teams through diversity of thought, and how Element Bio's culture is rooted in respect, authenticity, and collaboration. He also dives into how AI is transforming HR and talent management, why the bio life sciences industry is poised for a major turnaround, and what he sees driving investment in the sector heading into 2026. Plus, Keystone's Vicky Rayel closes out the episode with practical career development advice in Coach's Corner.

What happens when science education is designed as a relational, exploratory process rather than a rigid set of steps? In this episode, Claire de Mezerville López and Nikki Chamblee welcome science educator and restorative practitioner Kate Shapero to the Restorative Pedagogies series of the Restorative Works! Podcast to examine how restorative practices can transform the science classroom. Kate reflects on curiosity, experimentation, and learning from mistakes as essential elements of scientific thinking—and how these processes depend on trust, emotional safety, and strong relationships. Through stories from her classroom, she illustrates how student-led exploration, play, and collaborative problem-solving foster both scientific understanding and social-emotional growth. The conversation explores how restorative practices support risk-taking, perseverance, and teamwork in scientific inquiry, while also developing communication and relational skills that extend beyond the classroom. Kate invites educators to see restorative practices not as separate from content, but as integral to how students learn, collaborate, and engage deeply with science and with one another. Kate Shapero is a Science Education and Restorative Practices Specialist with over 20 years of experience. After completing her undergraduate degree, she developed and taught science curriculum in independent and alternative schools in the Philadelphia area. Working with pre-K through postgraduate learners, she specializes in progressive curriculum design that is experiential, meaningful, and joyful. As a restorative practitioner, Kate collaborates with students, teaching teams, classroom communities, parent groups, and administrative staff to improve community relational health. Kate's current work includes facilitation, coaching, and professional development. She earned a Bachelor of Science in Bioscience and Biotechnology from Drexel University in 2003 and a Master of Restorative Practices and Education from the IIRP Graduate School in 2010. Tune in to explore how integrating restorative practices into lesson plans can transform the science classroom.

Ashley Beckwith is the founder and CEO of Foray Bioscience, where she and her team leverage plant cell culture to createpredictable access to the plants and plant products the world needs, by growing them from the cell up. Ashley's path into the world of plants has been a curious one. She holds a Ph.D. in Mechanical Engineering from MIT and hasbeen innovating at the intersection of biology, materials, and manufacturing for over a decade. Her award-winning Ph.D. research led to the first demonstration of lab-grown “wood”, combining principles of tissue engineering and plant culture to grow structured plant materials in the lab. Now, Ashley leads Foray's team of plant biologists, process engineers, software developers, and machine learningexperts to make plant cell and tissue culture predictable and accessible for applications from micropropagation to fabricated seed production. 

For this episode, we are joined by Amy Toth, Professor in Ecology, Evolution, and Organismal Biology at Iowa State University, and Matt O'Neal, a Wallace Chair for Sustainable Agriculture and Professor in the Plant Pathology, Entomology, and Microbiology Department, also at Iowa State University. They were here to discuss their article from BioScience's forthcoming special issue on One Health, entitled, "Can Native Vegetation in Agroecosystems Provide a Net Benefit for Pollinators, Despite Pesticide Use?" 

Join hosts Kieren Sharma (Artificially Ever After podcast, University of Bristol) and Andrew Page (MicroBinfie podcast, Origin Sciences) for a compelling live panel discussion exploring the dynamic intersection of artificial intelligence and the biosciences. In this episode, our expert panel discusses:

The world faces mounting pressure to accelerate sustainable innovation at the intersection of food, health and industrial production, but moving from scientific discovery to scaled impact remains complex. From improving crop resilience and reducing environmental footprints to building healthier communities and more sustainable supply chains, bioscience innovations have become critical tools in tackling global sustainability challenges. This webinar, hosted by Innovation Forum in partnership with the Iowa Economic Development Authority explored how some of the latest bioscience breakthroughs are addressing these pressing issues. We look at emerging trends shaping the next wave of sustainable innovation, the technologies driving impact, and how organisations are applying bioscience. As a case study, we examined how Iowa is emerging as a key hub for the biosciences, bringing together agriculture technology, medical innovation, and industrial biotechnology in one ecosystem. What we discussed… Which bioscience breakthroughs from the past year are driving measurable sustainability impact, and how they came about What to watch for in 2026: scaling technologies, new applications, and the role of advanced technology in enabling sustainable innovation What drives success in biosciences: fostering innovation internally, building strategic partnerships, and leveraging ecosystems to deliver sustainable solutions

January 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Sword Health acquires Kaia Health for $285M, expanding AI Care platform into Germany's 70M+ person reimbursement system Flo Health and Mayo Clinic study finds U.S. women lag behind UK, Canada, and Australia in recognizing perimenopause symptoms Life Biosciences receives FDA clearance for first human trial of partial cellular reprogramming, targeting glaucoma using gene therapy More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Tiffany Libby for a clear, science-forward conversation on supplements, cellular energy, and why NAD biology has become such a focal point in modern longevity discussions. As interest in “aging better” grows, this episode cuts through hype to explore what NAD optimization can—and cannot—realistically do for skin and whole-body health.Dr. Libby brings a rare perspective to the conversation. As a board-certified dermatologist and Director of Mohs Surgery at Brown University Health, her work spans both skin cancer care and cosmetic dermatology, treating patients across decades of life. That long view has shaped her understanding of longevity not as youth preservation, but as maintaining resilience, repair capacity, and function over time—especially in the face of inflammation, environmental stress, and chronic disease.Much of the discussion centers on why supplements, particularly NAD boosters, are having a cultural moment. Dr. Libby explains that this surge reflects a gap in the healthcare system itself—one that prioritizes treatment over prevention. While supplements can offer support, she emphasizes they are not shortcuts. Longevity still rests on fundamentals: sleep, nutrition, movement, stress regulation, and inflammation control.The episode offers a practical breakdown of NAD (nicotinamide adenine dinucleotide), explaining its role in mitochondrial energy production, DNA repair, and cellular defense. As NAD levels decline with age, skin becomes less efficient at repairing damage, producing collagen, and maintaining barrier integrity. Crucially, Dr. Libby explains why NAD itself can't be absorbed directly—and why precursors like nicotinamide riboside (NR) matter instead.Throughout the conversation, skepticism and safety remain central themes. In an underregulated supplement space, quality, dosing, and clinical validation matter. From a dermatologic standpoint, supporting mitochondrial health may help skin function closer to its biological potential—but only when paired with evidence-based care and realistic expectations.Listen to the full episode of Skin Anarchy to hear Dr. Tiffany Libby unpack the science of NAD, cellular energy, and why longevity begins with supporting biology—not chasing promises.SHOP TRU NIAGENDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

We love to hear from our listeners. Send us a message.Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company's progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou's allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic platform using clinical and translational data. They also cover pivotal Phase 3 trial planning, regulatory considerations, and what to expect next from Caribou's broader pipeline, including its BCMA-targeted program in multiple myeloma.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Guy Wilson visits with Tom and Jason in Starkville as a Platinum sponsor of the 2025 Row Crop Short Course.  Find out more at https://www.greenlightbiosciences.com/ For more episodes from the Crop Doctors, visit our website at http://extension.msstate.edu/shows/mississippi-crop-situation

Todd Harris, CEO and Co-Founder of Tyra Biosciences, is focused on developing a selective inhibitor for FGFR3, a protein implicated in bladder cancer and childhood dwarfism. The company has developed the SNAP discovery platform to accelerate structure-based drug design targeting this specific protein, while avoiding effects on related proteins to minimize significant side effects. Their lead drug candidate has the potential to become a primary well-tolerated oral monotherapy, shifting the treatment paradigm for cancer patients to prevent recurrence and for children to allow for more typical bone growth. Todd explains, "We are taking a novel step to a set of conditions, genetic conditions in FGFR3 biology that have long been known, that others have attempted to address, but where the underlying chemistry hasn't had the necessary selectivity to really be able to make progress. FGFR3 biology is implicated both in bladder cancer and in kids with dwarfism and short stature conditions. And there have long been chemical matter drugs that can inhibit FGFR3, but also inhibit close family members, including FGFR1 and 2. These close family members, the nature of the close family members, make it very challenging to make a drug that is a drug candidate that selectively inhibits FGFR3 while sparing FGFR1, 2, and 4."   "And it was a challenge we took on because we felt like we could meaningfully improve the outcomes for patients by doing so. FGFR3 has important biology in bone and cancer, but FGFR1 and 2 have important biology as well and can lead to side effects when inhibited at the same time as FGFR3. So our attempt to make a selective inhibitor is really an effort to minimize off-target tolerability effects, things that can affect, like pain in your nails, blistering of hands and feet, and elevated phosphate levels when taking the pan FGFR drugs. And then just focus on a drug that can inhibit FGFR3, avoid that type of toxicity, and be able to more meaningfully impact these genetic conditions." #TyraBio #TyraBiosciences #PrecisionMedicine #BladderCancer #RareDiseases #Achondroplasia #Biotechnology #DrugDevelopment #FGFR3 #Innovation #ClinicalTrials #Oncology #PediatricMedicine #StructureBasedDrugDesign tyra.bio Download the transcript here 

Todd Harris, CEO and Co-Founder of Tyra Biosciences, is focused on developing a selective inhibitor for FGFR3, a protein implicated in bladder cancer and childhood dwarfism. The company has developed the SNAP discovery platform to accelerate structure-based drug design targeting this specific protein, while avoiding effects on related proteins to minimize significant side effects. Their lead drug candidate has the potential to become a primary well-tolerated oral monotherapy, shifting the treatment paradigm for cancer patients to prevent recurrence and for children to allow for more typical bone growth. Todd explains, "We are taking a novel step to a set of conditions, genetic conditions in FGFR3 biology that have long been known, that others have attempted to address, but where the underlying chemistry hasn't had the necessary selectivity to really be able to make progress. FGFR3 biology is implicated both in bladder cancer and in kids with dwarfism and short stature conditions. And there have long been chemical matter drugs that can inhibit FGFR3, but also inhibit close family members, including FGFR1 and 2. These close family members, the nature of the close family members, make it very challenging to make a drug that is a drug candidate that selectively inhibits FGFR3 while sparing FGFR1, 2, and 4."   "And it was a challenge we took on because we felt like we could meaningfully improve the outcomes for patients by doing so. FGFR3 has important biology in bone and cancer, but FGFR1 and 2 have important biology as well and can lead to side effects when inhibited at the same time as FGFR3. So our attempt to make a selective inhibitor is really an effort to minimize off-target tolerability effects, things that can affect, like pain in your nails, blistering of hands and feet, and elevated phosphate levels when taking the pan FGFR drugs. And then just focus on a drug that can inhibit FGFR3, avoid that type of toxicity, and be able to more meaningfully impact these genetic conditions." #TyraBio #TyraBiosciences #PrecisionMedicine #BladderCancer #RareDiseases #Achondroplasia #Biotechnology #DrugDevelopment #FGFR3 #Innovation #ClinicalTrials #Oncology #PediatricMedicine #StructureBasedDrugDesign tyra.bio Listen to the podcast here 

For this episode, we're joined by journalist Paul Koberstein, who was here to discuss his first book, Canopy of Titans, which is about the connection between forests and climate. In particular, the book focuses on the Pacific Coastal Temperate Rainforest, which constitutes one of the world's most important carbon stores. You can read recent expose on timber industry misinformation here.  

In this special holiday replay episode, we revisit our conversation with Ashley Beckwith, founder of Foray Biosciences, who shares her groundbreaking work in plant cell culture and tissue engineering. Growing up in Colorado, Ashley watched forests disappear to housing development and wildfire—experiences that sparked her lifelong mission to reimagine how we produce plant materials. After training as an engineer and working in medical device development, she pivoted to apply tissue engineering concepts to plants, initially exploring lab-grown wood before discovering a more fundamental problem: the lack of accessible, efficient plant cell culture processes. Today, Foray develops fabricated seeds for forest restoration, creates harvest-free plant products, and builds AI-powered tools to accelerate plant science R&D. Ashley explains why plant cells are the fundamental building blocks for everything from molecules to materials to entire ecosystems, and how her company is working to solve the seed shortage crisis that prevents us from restoring 94% of post-wildfire sites. She also discusses the potential for de-extinction of recently lost plant species in California and the importance of creating regenerative rather than extractive relationships with plant systems. This conversation explores the intersection of synthetic biology, forestry, and biomanufacturing while reminding us that we are all, whether we know it or not, plant people.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Holiday Greetings and Stranger Things on Broadway(00:04:41) - Introducing Ashley Beckwith and Foray Biosciences(00:07:17) - Growing Up in Colorado: Watching Forests Disappear(00:10:48) - From Medical Engineering to Plant Biology(00:15:00) - The Lab-Grown Wood Experiment(00:18:58) - Understanding Plant Cells as Versatile Production Agents(00:25:00) - Fabricated Seeds for California Biodiversity Restoration(00:33:00) - Addressing the Wildfire Restoration Seed Shortage(00:42:00) - Building the Plant Operating System with AI(00:50:00) - Why We're All Plant PeopleLinks and Resources:Foray Biosciences⁠⁠SF500 (Argentinian Global Venture Fund)⁠⁠Syensqo Corporate Venture Fund⁠⁠H.C. Wainwright⁠⁠University of Vermont - Dr. Steve Keller⁠⁠University of Maryland - Dr. Matt FitzpatrickForay Biosciences154. No Trees Were Harmed: Symmetry Wood's Gabe Tavas on Growing Wood from WasteTopics Covered: developmental biology, morphology, morphospace, planarians, electroceuticals, bioelectricity, tissue regeneration, biomedical applications, holidays, ChristmasHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren't yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he's especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

How much plastic are we actually absorbing and what's it doing to our health?In this eye-opening episode, I'm joined by Dr. Stephanie Wright, one of the UK's leading scientists in microplastic research, to explore what happens when plastic pollution doesn't just affect the environment, but our bodies too.We dive into:

If you're a moth trying to stay uneaten, there are competing strategies. Some moths rely on camouflage, trying to blend in. Other moths take the opposite approach: They're bold and bright, with colors that say “don't eat me, I'm poison.” Biologist Iliana Medina joins Host Flora Lichtman to describe a study that placed some 15,000 origami moths in forests around the world to investigate which strategy might work best. Then, mammologist Anderson Feijó and evolutionary biologist Rafaela Missagia join Flora to dive into another evolutionary conundrum: why so many rodents have thumbnails. Guests: Dr. Iliana Medina Guzman is a Senior Lecturer in the School of BioSciences at the University of Melbourne in Australia.Dr. Anderson Feijó is a mammal curator at the Field Museum in Chicago. Dr. Rafaela Missagia is an assistant professor at the University of São Paulo in Brazil.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.